Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing


Looking for our most recent market research report on this topic? Click here.

ISR believes the rise of risk-based monitoring (RBM) is a result of several forces acting on the pharmaceutical industry. First, electronic data capture (EDC) technology is now the de facto standard for site/ patient data capture. Second, the patent cliff and declining R&D productivity rates have conspired to “force” pharmaceutical companies to look at ways to cut costs, while increasing efficiency. Third, regulators have begun to output guidance documents that center on alternative drug development models and processes (risk-based monitoring, adaptive trials, electronic data as source data), making it less risky for sponsors to employ these methodologies/ strategies.

This report provides the pharmaceutical industry and its service providers with “peer-based” guidance and best-practices for the adoption, use, and outsourcing of risk-based monitoring.



  • Sponsors’ interests in and use of RBM studies, why RBM is gaining momentum, what is driving adoption, and a high-level look at sponsors’ expected financial and operational outcomes of RBM studies
  • Real-world lessons-learned, including advice for individuals and companies wanting to implement RBM studies
  • Study types that are seen as most appropriate for RBM and which department are involved in the planning of these studies
  • On-the-ground suggestions for improving the RBM regulatory and training processes
  • Critical technologies are most important to running a successful RBM-based trial and which are most difficult to implement
  • The percentage of RBM studies outsourced, the preferred types of service providers, and most important service provider attributes effecting selection

For sponsors: Use this information to help drive RBM adoption in your organization, avoid pitfalls that might stagger RBM growth, Inform your data infrastructure strategies, and benchmark the use of RBM.
For service providers: Better understand the inner working of sponsors as it relates to the adoption of RBM models and craft better messages and service offerings to account for these views.

  1. Executive Summary
  2. RBM Awareness and Definition
  3. Best Practices & Operational Impact of RBM
  4. Sponsor Perception and Use of RBM
  5. Data and Technology
  6. Outsourcing Environment
  7. RBM Economics
  8. Respondent Demographics

ISR understands that you’re looking for confidence in your market research. With ISR, you’ll consistently receive

  • Focused Domain Expertise — We’ve operated in pharmaceuticals for over 15 years and because it’s our sole focus, our domain expertise brings value to the work that “generalist” researchers can’t deliver.
  • Genuine Research Expertise — Our market research experience has developed over 20 years in many dynamic industries.  We capture appropriate sample sizes, given the research objectives, and we use appropriately sophisticated statistics to uncover everything that’s real and to give you confidence in your decisions. Read our Six Questions to Ask About Your Market Research to learn more about why our industry expertise sets us apart.
  • Transparency — If you’re like many, you’ve been disappointed more than once by research providers who fail to live up to their promises, providing you with their “professional judgment” in place of sound data; and suspect contacts instead of real decision-makers. We deliver the beliefs, attitudes, and intentions of people who matter – and we’ll prove it by showing you the titles of your respondents.

For additional questions about any of ISR’s reports or custom research services, please contact us at info@ISRreports.com.

Additional information


, ,


There are no reviews yet.

Be the first to review “Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing”